Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Feb;19(2):256–259. doi: 10.1128/aac.19.2.256

Evaluation of ceforanide as treatment for staphylococcal and streptococcal endocarditis.

R H Cooper, C B Savitch, W P Joseph, J Mills
PMCID: PMC181404  PMID: 7347561

Abstract

Ceforanide administered parenterally twice daily was used as the sole agent to treat 17 patients with right-sided endocarditis due to Staphylococcus aureus or nonenterococcal streptococci. Fifteen patients were cured of their original infection. Two patients were withdrawn from the study. One patient was transferred to another hospital 4 days after ceforanide therapy was initiated, and the other was changed to a different antibiotic regimen when his viridans streptococcus proved tolerant to ceforanide. The intramuscular form of ceforanide was well tolerated. It was stopped in two patients after week 3 of therapy because of adverse effects, possibly related to the study drug. These findings resolved with discontinuation of the ceforanide, and no additional antimicrobial therapy was necessary. Two patients who continued to abuse drugs intravenously during the study developed bacteremia with new organisms and required additional antimicrobial therapy. Ceforanide proved to be a useful agent in the treatment of right-sided endocarditis due to susceptible S. aureus and nonenterococcal streptococci.

Full text

PDF
256

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Denny A. E., Peterson L. R., Gerding D. N., Hall W. H. Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. Arch Intern Med. 1979 Sep;139(9):1026–1031. [PubMed] [Google Scholar]
  2. Goldman P. L., Petersdorf R. G. Significance of methicillin tolerance in experimental staphylococcal endocarditis. Antimicrob Agents Chemother. 1979 Jun;15(6):802–806. doi: 10.1128/aac.15.6.802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Musher D. M., McKenzie S. O. Infections due to Staphylococcus aureus. Medicine (Baltimore) 1977 Sep;56(5):383–409. doi: 10.1097/00005792-197709000-00002. [DOI] [PubMed] [Google Scholar]
  4. Peterson L. R., Gerding D. N., Hall W. H., Schierl E. A. Medium-dependent variation in bactericidal activity of antibiotics against susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 1978 Apr;13(4):665–668. doi: 10.1128/aac.13.4.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Smyth R. D., Pfeffer M., Glick A., Van Harken D. R., Hottendorf G. H. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother. 1979 Nov;16(5):615–621. doi: 10.1128/aac.16.5.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Tuazon C. U., Cardella T. A., Sheagren J. N. Staphylococcal endocarditis in drug users. Clinical and microbiologic aspects. Arch Intern Med. 1975 Dec;135(12):1555–1561. [PubMed] [Google Scholar]
  7. Watanakunakorn C. Antibiotic-tolerant Staphylococcus aureus. J Antimicrob Chemother. 1978 Nov;4(6):561–568. doi: 10.1093/jac/4.6.561. [DOI] [PubMed] [Google Scholar]
  8. Weaver S. S., LeBlanc B. M., Bodey G. P. BL-S786 (ceforanide), a new parenteral cephalosporin: in vitro studies. Antimicrob Agents Chemother. 1979 Feb;15(2):318–322. doi: 10.1128/aac.15.2.318. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES